EE200100631A - Amlodipiini ja atorvastatiini ühised eelravimid - Google Patents

Amlodipiini ja atorvastatiini ühised eelravimid

Info

Publication number
EE200100631A
EE200100631A EEP200100631A EEP200100631A EE200100631A EE 200100631 A EE200100631 A EE 200100631A EE P200100631 A EEP200100631 A EE P200100631A EE P200100631 A EEP200100631 A EE P200100631A EE 200100631 A EE200100631 A EE 200100631A
Authority
EE
Estonia
Prior art keywords
amlodipine
atorvastatin
common prodrugs
prodrugs
common
Prior art date
Application number
EEP200100631A
Other languages
English (en)
Estonian (et)
Inventor
Chang George
Seiichi Hamanaka Ernest
Lawrence Lamattina John
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100631A publication Critical patent/EE200100631A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
EEP200100631A 1999-05-27 2000-03-20 Amlodipiini ja atorvastatiini ühised eelravimid EE200100631A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13660899P 1999-05-27 1999-05-27
PCT/IB2000/000313 WO2000073298A1 (en) 1999-05-27 2000-03-20 Mutual prodrugs of amlodipine and atorvastatin

Publications (1)

Publication Number Publication Date
EE200100631A true EE200100631A (et) 2003-02-17

Family

ID=22473579

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100631A EE200100631A (et) 1999-05-27 2000-03-20 Amlodipiini ja atorvastatiini ühised eelravimid

Country Status (41)

Country Link
US (1) US6486182B1 (xx)
EP (1) EP1180102B9 (xx)
JP (1) JP2003500487A (xx)
KR (1) KR20020012247A (xx)
CN (1) CN1352640A (xx)
AP (1) AP2001002345A0 (xx)
AR (1) AR022344A1 (xx)
AT (1) ATE268764T1 (xx)
AU (1) AU3313900A (xx)
BG (1) BG106149A (xx)
BR (1) BR0011006A (xx)
CA (1) CA2375372C (xx)
CO (1) CO5170457A1 (xx)
CZ (1) CZ20014229A3 (xx)
DE (1) DE60011424T2 (xx)
DK (1) DK1180102T3 (xx)
DZ (1) DZ3048A1 (xx)
EA (1) EA200101130A1 (xx)
EE (1) EE200100631A (xx)
ES (1) ES2220426T3 (xx)
GT (1) GT200000078A (xx)
HK (1) HK1046282A1 (xx)
HN (1) HN2000000075A (xx)
HR (1) HRP20010856A2 (xx)
HU (1) HUP0201433A2 (xx)
IL (1) IL145947A0 (xx)
IS (1) IS6135A (xx)
MA (1) MA26736A1 (xx)
MX (1) MXPA01012125A (xx)
NO (1) NO20015756L (xx)
OA (1) OA11950A (xx)
PA (1) PA8495701A1 (xx)
PE (1) PE20010169A1 (xx)
PL (1) PL353483A1 (xx)
PT (1) PT1180102E (xx)
SK (1) SK16792001A3 (xx)
SV (1) SV2002000082A (xx)
TN (1) TNSN00113A1 (xx)
TR (1) TR200103391T2 (xx)
WO (1) WO2000073298A1 (xx)
ZA (1) ZA200109691B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
EP1909848A2 (en) * 2005-08-01 2008-04-16 PSivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
JP4905738B2 (ja) 2007-10-10 2012-03-28 Nok株式会社 アキュムレータ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
EP1180102B1 (en) 2004-06-09
DK1180102T3 (da) 2004-09-06
PE20010169A1 (es) 2001-02-10
CA2375372A1 (en) 2000-12-07
CZ20014229A3 (cs) 2003-01-15
BG106149A (en) 2002-05-31
NO20015756D0 (no) 2001-11-26
HUP0201433A2 (en) 2002-08-28
CN1352640A (zh) 2002-06-05
WO2000073298A1 (en) 2000-12-07
EP1180102B9 (en) 2005-03-02
MA26736A1 (fr) 2004-12-20
ATE268764T1 (de) 2004-06-15
ZA200109691B (en) 2002-11-26
DE60011424D1 (de) 2004-07-15
JP2003500487A (ja) 2003-01-07
KR20020012247A (ko) 2002-02-15
ES2220426T3 (es) 2004-12-16
EA200101130A1 (ru) 2002-04-25
US6486182B1 (en) 2002-11-26
OA11950A (en) 2006-04-13
TNSN00113A1 (fr) 2005-11-10
HRP20010856A2 (en) 2002-12-31
BR0011006A (pt) 2002-02-19
TR200103391T2 (tr) 2002-04-22
DE60011424T2 (de) 2005-08-25
HN2000000075A (es) 2001-02-02
PA8495701A1 (es) 2001-12-14
IS6135A (is) 2001-10-30
PT1180102E (pt) 2004-08-31
PL353483A1 (en) 2003-11-17
HK1046282A1 (zh) 2003-01-03
AR022344A1 (es) 2002-09-04
SK16792001A3 (sk) 2003-03-04
CO5170457A1 (es) 2002-06-27
MXPA01012125A (es) 2002-06-04
DZ3048A1 (fr) 2004-03-27
CA2375372C (en) 2007-01-09
EP1180102A1 (en) 2002-02-20
IL145947A0 (en) 2002-07-25
AU3313900A (en) 2000-12-18
SV2002000082A (es) 2002-02-05
AP2001002345A0 (en) 2001-12-31
GT200000078A (es) 2001-11-16
NO20015756L (no) 2002-01-24

Similar Documents

Publication Publication Date Title
EE200100632A (et) Amlodipiini ja atorvastatiini ühine sool
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
DK1491193T3 (da) Terapeutiske kombinationer omfattende amlodipin og atorvastatin
EE04904B1 (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
EE200100631A (et) Amlodipiini ja atorvastatiini ühised eelravimid
IS7089A (is) Lyfjasamsetningar amlódipíns og atórvastatíns
EE200200146A (et) Loteprednooli ja antihistamiinsete ainete uudne kombinatsioon
EE200400048A (et) Atorvastatiinkaltsiumi kristalsed vormid VI ja VII
AU2001283085A1 (en) Synergistic effect of amlodipine and atorvastatin
NO20015128L (no) Synergistiske virkninger av amlodipin og atorvastatin
FI19992219A (fi) Yhdistetty difibrillaattori ja sydäntahdistin
SI1180102T1 (en) Mutual prodrugs of amlodipine and atorvastatin
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
GB0027410D0 (en) Mutual prodrug of amlodipine and atorvastatin
FI990281A (fi) Liitos erityisesti rakenne-elementtejä varten ja rakenne-elementti
FIU20000507U0 (fi) Clinikit DiagnoPacks ja Openkit-konsepti
ZA200108685B (en) Synergistic effects of amlodipine and atorvastatin.
FI4171U1 (fi) Hautakivi
FI20010262A0 (fi) Liitin ja liittimen irtopala
FI19992634A (fi) Menetelmä kanavan muodostamiseksi ja kanava

Legal Events

Date Code Title Description
HD1A Correction of address